India’s Pharmaceutical Export Supply Chain — SSL’s Role in the $27 Billion Opportunity

India exported $27.9 billion of pharmaceutical products in FY2023-24 — the largest pharma export value in India’s history, and a number that the government’s Vision 2030 plans to grow to $65 billion. Behind every dollar of pharmaceutical export is a supply chain: APIs manufactured in Hyderabad or Ahmedabad, formulated into finished dosage forms in factories across India, packaged and quality-tested, and then moved to export ports for shipment to the USA, UK, Africa, Southeast Asia, and the rest of the world.

The India-side first mile of this export supply chain — from factory to port — is where SSL operates. And it is a segment that most people do not think about when they imagine pharmaceutical exports, but one that is critical to the entire enterprise.

The India-Side Pharma Export Challenge

A pharmaceutical manufacturer in Hyderabad exporting to the UK faces a specific logistics problem: their finished goods must move from their Hyderabad factory to JNPT (Mumbai) or Chennai Port in a manner that maintains GDP compliance throughout the India-side journey. The exported goods are temperature-sensitive API or finished dosage forms. Any temperature excursion during the factory-to-port movement invalidates the batch documentation and, in the worst case, destroys the product.

But maintaining GDP compliance on a 700-km road journey from Hyderabad to JNPT is not simply a matter of using a reefer truck. It requires: a validated reefer unit with documented temperature mapping, continuous temperature monitoring with downloadable logs for the quality file, a chain of custody process that tracks who handled the cargo and when, documentation that aligns with the export dossier, and a logistics provider whose GDP compliance is auditable by the importing country’s regulatory authority.

SSL provides all of this. Our pharma cold chain team has been through regulatory audits by quality teams from UK, USA, Germany, and other regulated markets. The documentation discipline that GDP compliance requires is built into our operating SOPs — not bolted on as an afterthought.

The API Manufacturing Belt — SSL’s Coverage

India’s pharmaceutical API manufacturing is concentrated in a few key clusters, and SSL has direct logistics coverage of all of them:

Hyderabad: India’s largest API manufacturing cluster by value. Major API manufacturers including Dr. Reddy’s Laboratories, Divi’s Laboratories, Aurobindo Pharma, and Laurus Labs all have significant Hyderabad operations. SSL manages factory-to-JNPT and factory-to-Chennai logistics for Hyderabad pharma export shipments.

Ahmedabad/Gujarat: A major API and finished dosage manufacturing cluster. Companies like Zydus, Torrent, Sun Pharma (Vadodara), and Cadila operate significant Gujarat pharma manufacturing. SSL’s Gujarat-origin EXIM network covers factory-to-Mundra and factory-to-JNPT movements.

Baddi-BBN (Himachal Pradesh): India’s largest pharma manufacturing zone by plant count, with over 500 pharma units including Sun Pharma, Torrent, Cipla, Mankind, and Lupin. SSL’s Baddi operations cover the critical factory-to-rail/road first mile to export ports.

Pune/Maharashtra: Significant pharma manufacturing for both domestic and export markets. SSL’s Pune operations cover factory-to-JNPT logistics — particularly important given JNPT’s dominance in India’s pharmaceutical export volumes.

Africa: India’s Fastest Growing Pharma Export Market

Africa now accounts for approximately 20% of India’s pharmaceutical exports — and is the fastest-growing destination for Indian generics. In countries like Nigeria, Kenya, Tanzania, and Ethiopia, Indian pharmaceutical companies supply 60-80% of all generic medicines consumed. SSL manages both the India-side supply chain (factory-to-port) and the in-country distribution coordination for several pharma export markets.

The logistics challenge for Africa-bound pharma is specific: the products must maintain GDP compliance from Indian factory to African distribution centre — a journey that may involve road transport, port handling, 18-22 days ocean transit, and destination country customs clearance, with temperature control required throughout. SSL’s end-to-end EXIM coordination — covering India-side road transport, port handling coordination, shipping line management, and in-country liaison — is the supply chain management capability that Indian pharma exporters increasingly need as they scale their African market operations.

Contact SSL’s pharma EXIM team: corporatesales@sslpl.in | +91-92978 78787